We manufacture clinical-grade pluripotent stem cells
The potential of cell therapies for hard-to-treat conditions has been limited by the complex and costly logistics of autologous treatments. Therapy cells are produced “from the patient, for the patient.”
Off-the-shelf, allogenic approaches – where treatments are manufactured from a healthy donor’s cells and used for multiple patients – have moved into the spotlight as a way to accelerate time-to-patient and reduce cost significantly. Boosting immune compatibility of donor cells and ensuring their fit for therapeutic purposes is critical to realize such advanced therapy medicinal products.
This is where RHEINCELL excels.
We produce GMP-grade human induced pluripotent stem cells (iPSCs) from a unique source of clinically-approved, donor-consented umbilical cord blood units. Furthermore, we expedite allogenic approaches with a collection of HLA-homozygous iPSCs that reduce transplant rejection. Partnering with innovative developers of off-the-shelf iPSC-based therapies, we advance cell therapies where they begin: at the cell.
what we do
The latest news from RHEINCELL
RheinCell teams up with RegMedNet to shine a spotlight on iPSCs
RegMedNet has just announced a new In Focus feature taking a close look at how induced pluripotent stem cells can catalyze the advancement of novel cell therapies. Prepared in collaboration with RheinCell experts, the feature explores biological, clinical and commercial characteristics of iPSCs as ideal starting materials.
A NEW PUBLICATION ON THE POTENTIAL OF IPSCS
The April issue of the European Biopharmaceutical Review includes a thought leadership article authored by Thomas Marx and Boris Greber. In it, they explore the potential of induced pluripotent stem cells as meticulously defined starting materials for advanced therapies.
THOMAS MARX AND BORIS GREBER DISCUSS THE POTENTIAL OF IPSCs
In an informative interview with Michael Adeniya, Portfolio Director of Phacilitate Exchange, Boris Greber and Thomas Marx answer questions about the position of induced pluripotent stem cells in today’s advanced therapies market and the transformative power latent in their clinical application.